

Influence of vitamin D supplementation on muscle strength and exercise capacity in Mongolian schoolchildren: a randomised controlled trial

Davaasambuu Ganmaa^{1,2†}

Stephanie Hemmings³

David A. Jolliffe⁴

Uyanga Buyanjargal⁵

Gantsetseg Garmaa⁵

Unaganshagai Adiya⁵

Tumenulzii Tumurbaatar⁵

Khulan Dorjnamjii⁵

Enkhtsetseg Tserenkhuu⁶

Sumiya Erdenenbaatar⁵

Enkhjargal Tsendjav⁵

Nomin Enkhamgalan⁵

Chuluun-Erdene Achtaï⁵

Yagaantsetseg Talhaasuren⁶

Tuya Byambasuren⁷

Erdenetuya Ganbaatar⁸

Erkhembulgan Purevdorj⁵

Adrian R Martineau^{4†}

¹Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

²Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

³School of Sport and Health Sciences, University of Brighton, Eastbourne BN20 7SP, UK

⁴Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK

⁵Mongolian Health Initiative, Royal Plaza, Bayanzurkh District, Ulaanbaatar 13312, Mongolia

⁶Global Laboratory, Royal Plaza, Bayanzurkh District, Ulaanbaatar 13312, Mongolia

⁷Mongolian Ministry of Health, Sukhbaatar District, Ulaanbaatar 14210, Mongolia

⁸Mongolian National University of Medical Sciences, Sukhbaatar District, Ulaanbaatar 14210, Mongolia

† To whom correspondence should be addressed:

The Department of Nutrition, Harvard T.H. Chan School of Public Health, Building 2, Room 211, 655 Huntington Ave, Boston, Massachusetts 02115, USA; gdavaasa@hsph.harvard.edu, or

Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK; a.martineau@qmul.ac.uk.

ABSTRACT

Objective: To determine whether weekly oral vitamin D supplementation influences grip strength, explosive leg power, cardiorespiratory fitness or spirometric lung volumes in Mongolian schoolchildren.

Methods: Multicentre, randomised, double-blind, placebo-controlled clinical trial conducted in children aged 6-13 years at baseline attending 18 schools in Ulaanbaatar. The intervention was weekly oral doses of 14,000 IU vitamin D₃ (n=4418) or placebo (n=4433) for 3 years. Outcome measures were grip strength, standing long jump distance and serum 25-hydroxyvitamin D (25[OH]D) concentrations (determined in all participants), peak oxygen uptake (VO_{2peak}, determined in a subset of 632 participants using 20-metre multi-stage shuttle run tests) and spirometric outcomes (determined in a subset of 1,343 participants).

Results: 99.8% of participants had serum 25(OH)D concentrations <75 nmol/L at baseline, and mean end-study 25(OH)D concentrations in children randomised to vitamin D vs. placebo were 77.4 vs. 26.7 nmol/L (mean difference 50.7 nmol/L, 95% CI, 49.7 to 51.4). However, vitamin D supplementation did not influence mean grip strength, standing long jump distance, VO_{2peak}, spirometric lung volumes or peak expiratory flow rate, either overall or within sub-groups defined by sex, baseline 25(OH)D concentration <25 vs. ≥25 nmol/L or calcium intake <500 vs. ≥500 mg/day.

Conclusion: A 3-year course of weekly oral supplementation with 14,000 IU vitamin D₃ elevated serum 25(OH)D concentrations in Mongolian schoolchildren with a high baseline prevalence of vitamin D deficiency. However, this intervention did not influence grip strength, explosive leg power, peak oxygen uptake or spirometric lung volumes, either overall or in sub-group analyses.

KEY MESSAGES

What is already known on this topic?

Observational studies have reported that vitamin D deficiency associates with reduced muscle strength and peak oxygen uptake in children, but randomised controlled trials (RCT) of vitamin D supplementation to improve grip strength and cardiorespiratory fitness in this age-group have yielded conflicting results.

What this study adds

This Phase 3 multicentre RCT of vitamin D supplementation, conducted in Mongolian schoolchildren with a high baseline prevalence of asymptomatic vitamin D deficiency, found that a 3-year course of weekly oral supplementation with 14,000 IU vitamin D₃ was effective in elevating serum 25-hydroxyvitamin D concentrations. However this intervention did not influence participants' grip strength, long jump distance, peak oxygen uptake, spirometric lung volumes or peak expiratory flow rate, either overall or in sub-group analyses.

How this study might affect research, practice or policy

Taken together with results from another Phase 3 randomised controlled trial of vitamin D supplementation conducted in South African children, our findings do not suggest a role for weekly oral vitamin D supplementation to enhance muscle strength, peak oxygen uptake or respiratory function in schoolchildren in whom rickets has been excluded.

INTRODUCTION

Muscular strength and exercise tolerance in childhood are positive correlates of physical and mental health that associate with reduced cardiometabolic risk later in life.¹⁻⁴ Vitamin D plays a key role in supporting normal development and function of skeletal muscle, the lung and the heart.⁵⁻⁷ Vitamin D deficiency is common among children living in higher- and lower-income countries alike,⁸⁻¹¹ and has been reported to associate with lower muscle strength, poorer cardiorespiratory fitness and lower spirometric lung volumes in children and adolescents participating in observational studies.¹²⁻¹⁴ Numerous randomised controlled trials (RCTs) of vitamin D supplementation to improve muscle strength and power have been conducted in adults, with meta-analysis revealing small positive impacts.¹⁵ Fewer RCTs have been conducted in children, and these have yielded inconsistent results. One trial in male soccer players in Tunisia aged 8-15 years has reported improvements in jump, sprint and shuttle run outcomes,¹⁶ while another conducted in 12-14 year-old girls in the United Kingdom reported a statistically significant improvement in efficiency of movement, with trends towards improvements in jumping velocity and grip strength.¹⁷ Other RCTs conducted in children and adolescents living in Denmark,^{18 19} the United States,²⁰ Israel²¹ and Lebanon²² have reported null overall effects for outcomes including grip strength, leg press strength and swimming performance. No such trials have yet been conducted in Asia; moreover, there is a lack of large, multicentre trials examining the impact of prolonged (greater than one year) vitamin D supplementation on muscle strength, cardiorespiratory fitness and spirometric outcomes in children with a high baseline prevalence of vitamin D deficiency, regardless of setting.

An opportunity to address this gap in the literature arose during conduct of a phase 3 randomised controlled trial of vitamin D supplementation in 8,851 school children aged 6 – 13 years living in Mongolia who were given weekly oral vitamin D supplementation over 3 years.²³⁻²⁵ The primary aim of the trial was to test whether this intervention reduced risk of incident tuberculosis infection; null results for this outcome have been reported elsewhere.²³ This paper reports findings for secondary outcomes including grip strength and standing long jump distance, measured at annual intervals in all participants; peak oxygen uptake (VO_{2peak}), estimated using 20 metre shuttle run tests performed at annual intervals in a subset of 632 participants; and spirometric outcomes, measured at 3-year follow-up in a subset of 1,343 participants.

METHODS

Study Design, Setting, Participants and Randomisation

We conducted a parallel two-arm double-blind individually randomised placebo-controlled trial in eighteen public schools in Ulaanbaatar, Mongolia, as previously described.²³⁻²⁵ The primary outcome of the trial was acquisition of latent tuberculosis infection; the current manuscript reports effects of the intervention on pre-specified secondary outcomes relating to grip strength, explosive leg power, peak oxygen uptake and spirometric outcomes. Principal inclusion criteria were age 6-13 years at screening and attendance at a participating school; principal exclusion criteria were a positive QuantiFERON-TB Gold in-tube assay (QFT) result, presence of conditions associated with vitamin D hypersensitivity (primary hyperparathyroidism or sarcoidosis) or immunocompromise (taking immunosuppressant medication or cytotoxic therapy), use of vitamin D supplements, signs of rickets (all participants were screened for rickets via physical examination by a paediatrician), or intention to move from Ulaanbaatar within 4 years of enrolment. Eligible participants were individually randomised to receive a weekly capsule containing 14,000 IU (350 µg) vitamin D₃ or placebo for three years, with a one-to-one allocation ratio and stratification by school of attendance. Treatment allocation was concealed from participants, care providers, and all trial staff to maintain the double-blind. The trial is registered with clinicaltrials.gov (NCT02276755).

Baseline Procedures

At baseline, participants' parents were asked to complete questionnaires detailing their socioeconomic circumstances, lifestyle and dietary factors influencing vitamin D

status, and intake of foods previously shown to be major contributors to dietary calcium intake in urban Mongolia.²⁶ For all participants, height was then measured using a portable stadiometer (SECA, Hamburg, Germany), weight was measured using a Digital Floor Scale (SECA), grip strength was measured as described elsewhere²⁷ using a portable dynamometer (Takei Digital Grip Strength Dynamometer, Model T.K.K.5401, with the best of 2 readings for the dominant hand recorded, except where injury precluded measurement, where strength of the other hand was measured), and standing long jump distance was measured as described elsewhere²⁸ using a DiCUNO measuring tape, with the best of 2 readings recorded. In a subset of 620 children who additionally participated in the exercise sub-study, a 20-metre multi-stage shuttle run test was administered as described below to determine VO₂peak. A blood sample was drawn from all participants at baseline for separation and storage of serum for determination of baseline 25(OH)D concentrations as described below.

Follow-Up Procedures and Outcomes

During school terms, study participants had weekly face-to-face visits at which study capsules were administered and adverse events were recorded. During school holidays, children were either given a single bolus dose of up to 36,000 IU (shorter holidays), study staff travelled to participants homes to administer medication, or parents were supplied with sufficient trial medication to cover the holiday period, along with instructions on its storage and administration. Using the same methods as at baseline, all participants were re-assessed at 12-, 24- and 36-month follow-up for grip strength and long jump distance. Exercise sub-study participants additionally

completed 20-metre multi-stage shuttle run tests at 12-, 24- and 36-month follow-up, as described below. Spirometry sub-study participants additionally underwent spirometry testing at 36-month follow-up using a portable spirometer (spirolab III, Medical International Research, Rome, Italy) and performed according to ERS/ATS standards²⁹ to assess % predicted forced expiratory volume in one second (FEV1), % predicted forced vital capacity (FVC), % predicted FEV1/FVC, % predicted peak expiratory flow rate (PEFR) and % predicted forced expiratory flow over the middle one-half of the FVC (FEF25-75).

Measurement of vitamin D status

25(OH)D concentrations were determined in serum samples from baseline and 3-year follow-up using an enzyme-linked fluorescent assay (VIDAS 25OH Vitamin D total, bioMérieux, Marcy-l'Étoile, France). Non-zero 25(OH)D values were standardised using a published method,³⁰ utilising a set of 40 serum samples provided by DEQAS (the Vitamin D External Quality Assessment Scheme, <http://www.deqas.org/>). Total coefficient of variation (CV) was 7.9%, mean bias was 7.7% and the limit of quantitation (LOQ) was 20.2 nmol/L. Values below the LOQ were classified as < 20.2 nmol/L.

Exercise test

A 20-metre multi-stage shuttle run test was conducted using freely available recorded instruction (Shuttle run beep test, www.bleeptests.com). Two lines were marked 20 meters apart and an audible 'beep' signalled to participants the speed

required to run between them. Participants' number of completed laps were used to derive their estimated VO_{2peak} using a published formula.³¹

Sample Size and Statistical Methods

The sample size calculation for the main trial was based on the power needed to detect a clinically significant effect of the intervention on the primary endpoint (incident latent tuberculosis infection) as described previously [20]. For the exercise sub-study, assuming a standard deviation for VO_{2peak} of 6.5 ml/kg/min at 3-year follow-up,³¹ we calculated that a total of 334 participants (167 per arm) would need to be recruited and followed up to have 80% power to detect a clinically significant difference of 2 ml/kg/min between arms with 5% alpha. Allowing for 20% loss to follow-up, we originally estimated that a total of 420 participants (210 per arm) would need to be recruited to the exercise sub-study. Subsequently, we became concerned that rates of loss to follow-up might be higher than originally anticipated, and consequently the target sample size for this sub-study was increased to 614. Ultimately, the exercise sub-study over-recruited slightly (n=632). Spirometry was performed for a subset of children who participated in a bone health sub-study, powered to detect an effect of the intervention on radial speed of sound Z-scores as described elsewhere.²⁵

Estimated calcium intakes were calculated on the basis of parental responses to a food frequency questionnaire, as described elsewhere.²⁴. Anthropometric measurements and data on participants' age and sex were used to compute Z-scores for height-for-age and BMI-for-age, using the Canadian Pediatric Endocrine

Group who2007 Shiny App (https://cpeg-gcep.shinyapps.io/who2007_cpeg/) based on WHO 2007 growth reference data for 5-19 years.³² Serum 25(OH)D values were adjusted for seasonal variation prior to analysis using a sinusoidal model.³³ Outcomes measured over multiple years' follow-up were analyzed overall and in each sub-group using mixed models for repeated measures with fixed effects for treatment and time and treatment-by-time interaction, adjusted for school of attendance and random effects for individuals. Adjusted treatment mean differences at different time-points are presented with 95% confidence intervals, and significance tests were conducted for the treatment effect at each time point and the overall treatment-by-time interaction. Where overall P values were less than 0.05, we applied a Benjamini Hochberg procedure with a 10% false discovery rate³⁴ to the relevant family of P values to adjust for multiple comparisons. Outcomes measured at end-study only were analyzed using general linear models, adjusted for school of attendance. Pre-specified sub-group analyses were conducted according to participants' sex (males vs. females), baseline deseasonalised 25(OH)D concentration (<25 nmol/L vs. ≥25 nmol/L) and estimated calcium intake (<500 mg/day vs. ≥500 mg/day). The primary P-values for outcome modelling were the overall P values, i.e. those associated with the interaction between follow-up timepoint and treatment allocation.

Patient and Public Involvement

We consulted children and their parents / guardians on questionnaire design and acceptability of clinical measurements prior to implementation of the trial. Study findings were disseminated via community engagement events.

RESULTS

PARTICIPANTS

11,475 children were invited to participate in the study from September 2015 to March 2017 inclusive, of whom 9,814 underwent QFT testing: 8,851 QFT-negative children were randomly assigned to receive vitamin D or placebo (4418 vs. 4433, respectively) as previously described.²³ Of these, 632 children (302 vs. 330 randomised to vitamin D vs. placebo, respectively) also participated in the exercise sub-study, and 1343 children (666 vs. 677 randomised to vitamin D vs. placebo, respectively) underwent spirometry at 3-year follow-up (Figure 1). Table 1 shows participants' baseline characteristics: overall, mean age was 9.4 years and 49.3% were female. Mean deseasonalised baseline serum 25(OH)D concentration was 29.7 nmol/L (SD 10.5). Baseline characteristics were well balanced between participants randomised to vitamin D vs. placebo, both for those in the main trial and for participants contributing data to the exercise and spirometry sub-studies. Mean serum 25(OH)D concentration at 3-year follow-up was higher in the vitamin D group vs. the placebo group (77.4 vs. 26.7 nmol/L, respectively; mean difference 50.7 nmol/L, 95% CI, 49.7 to 51.4). 8549 participants contributed data to the analysis of grip strength; 8539 to the analysis of long jump distance; 611 to the analysis of cardiorespiratory fitness; and 1343 to the analysis of spirometric outcomes (Figure 1).

OUTCOMES

Allocation to vitamin D vs. placebo did not influence mean grip strength, either overall or in sub-groups defined by male vs. female sex, baseline 25(OH)D

concentration <25 vs. \geq 25 nmol/L or estimated calcium intake <500 vs \geq 500 mg/day (Table 2). Similarly, no effect of the intervention was seen on long jump distance, either overall or by sub-group, after correction for multiple comparisons testing (Table 3). Among exercise sub-study participants, allocation to vitamin D vs. placebo did not influence mean VO_{2peak} , either overall or within sub-groups defined by male vs. female sex, baseline 25(OH)D concentration <25 vs. \geq 25 nmol/L or estimated calcium intake <500 vs \geq 500 mg/day (Table 4). Among participants who underwent spirometry at 3-year follow-up, allocation to vitamin D vs. placebo did not influence % predicted FEV1, FVC, FEV1/FVC, PEFr or FEF₂₅₋₇₅ after correction for multiple comparisons testing, either overall or within sub-groups defined by male vs. female sex, baseline 25(OH)D concentration <25 vs. \geq 25 nmol/L or estimated calcium intake <500 vs \geq 500 mg/day (Table 5).

DISCUSSION

We present findings of the largest randomised controlled trial to investigate effects of vitamin D on muscle strength, peak oxygen uptake and spirometric lung volumes in children. Vitamin D deficiency was highly prevalent among the study population at baseline, and the intervention was highly effective in elevating serum 25(OH)D concentrations among participants who were randomised to receive it. However, this was not associated with any effect on any physiological outcome investigated, either overall or in sub-groups defined by baseline vitamin D status, sex or calcium intake.

Our findings contrast with those of observational studies reporting associations between low vitamin D status and reduced muscle strength and cardiorespiratory fitness,^{12 13} and chime with results of smaller RCTs, conducted in populations with lower prevalence of vitamin D deficiency, that have yielded null results.¹⁸⁻²² They are also consistent with the lack of effect seen for muscle strength and exercise outcomes in a similar trial conducted in South Africa,³⁵ and for other 'non-classical' outcomes in trials of weekly vitamin D supplementation in children.^{23-25 36-38} Inconsistency between positive findings of observational vs. null findings from interventional studies may reflect effects of confounding or bias in the former.³⁹ Lack of sub-group effects in participants with lower baseline vitamin D status or calcium intake suggests that neither of these factors modified the effects of vitamin D supplementation on outcomes investigated. We highlight that our null findings do not have relevance for children with symptomatic vitamin D deficiency, since those who were found to have signs of rickets were excluded from the trial, as it would not have been ethical to randomise them to placebo.

Our study has several strengths. The large sample size and low rates of loss to follow-up maximised our power to detect effects of the intervention, and the high prevalence of vitamin D deficiency and low calcium intake at baseline allowed us to rule out effects even in sub-groups who might have been expected to derive particular benefit from vitamin D replacement. The intervention was highly effective in elevating serum 25(OH)D concentrations into the physiological range. We also assessed a comprehensive range of outcomes relating to muscle and cardiorespiratory fitness, with assessments at more than one time-point to allow detection of any effects that may have differed with varying duration of supplementation.

Our study also has some limitations. Spirometry was assessed at 3-year follow-up only: accordingly, analyses testing the effect of allocation to vitamin D vs. placebo could not be adjusted for baseline. However, we have no reason to suspect significance imbalance in baseline values between groups, as the randomisation process was effective in distributing all other baseline characteristics evenly between children randomised to intervention vs. control arms. We also highlight that our findings relate to effects of weekly vitamin D supplementation specifically. It remains technically possible that daily supplementation might have a different effect, although the fact that weekly supplementation is effective in suppressing PTH and ALP concentrations in study participants^{25 37} suggests that this dosing regimen exerts the same physiological effects as would be expected with daily supplementation.

In conclusion, this large multicentre RCT of vitamin D supplementation, administered for 3 years to a population of children with low baseline 25(OH)D concentrations, did not show any effect of the intervention on muscle strength, cardiorespiratory fitness or spirometric outcomes. Taken together with null results from a similarly-designed

Phase 3 RCT conducted in CapeTown, South Africa,³⁵ our study does not suggest a role for weekly oral vitamin D supplementation to enhance muscle strength, peak oxygen uptake or respiratory function in schoolchildren in whom rickets has been excluded.

Acknowledgements

We thank all the children who participated in the trial, and their parents and guardians. We also thank independent members of the Data Safety Monitoring Board (Prof S.M. Fortune and Dr P.L. Williams, Harvard T.H. Chan School of Public Health; Profs M.F. Holick and C.R. Horsburgh, Boston University; Prof P. Enkhbaatar, University of Texas; and Dr. E. Chadraa, Minnesota State University); independent members of the Trial Steering Committee (Profs W.C. Willett, Edward L. Giovannucci and B.R. Bloom, Harvard T.H. Chan School of Public Health; Dr N. Naranbat, Gyals Medical Laboratory, Ulaanbaatar; and late Dr D. Malchinkhuu, National Center for Maternal and Child Health of Mongolia); board members at the Mongolian Health Initiative (Dr J. Tuyatsetseg, Mongolian University of Science and Technology; Dr J. Amarsanaa, Happy Veritas Laboratory, Ulaanbaatar; Drs P. Erkhembulgan and G. Batbaatar, Mongolian National University of Medical Sciences; Prof M.C. Elliott, Harvard University; and Mr. Ts. Munh-Orgil, Member of the Mongolian Parliament); and the following individuals for advice and helpful discussions: Dr Winthrop Burr (Anadyne Psychotherapy Inc) and Dr. Masae Kawamura at Qiagen USA.

Contributors

Contributors

DG and ARM conceived the study and contributed to study design and protocol development; SH contributed to design of outcome assessments of muscle strength and peak oxygen uptake. DG led on trial implementation, with support from UB, GG, UA, TT, KD, ET, SE, NE, C-E A, YT, TB, EG and EP. ET performed and supervised measurements of serum 25(OH)D concentrations. DG and ARM drafted the statistical analysis plan. DG, UB, ET and SE managed data. DG, ARM and DAJ accessed and verified the data underlying the study. DAJ conducted statistical analyses. ARM, DG and DAJ wrote the first draft of the trial report. All other authors made substantive comments thereon and approved the final version for submission.

Funding

This study was supported by an award from the United States National Institutes of Health, ref. 1R01HL122624-01.

Competing interests

ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd; support for attending meetings from Pharma Nord Ltd and Abiogen Pharma Ltd; receipt of consultancy fees from DSM Nutritional Products Ltd and Qiagen Ltd; receipt of a speaker fee from the Linus Pauling Institute; participation on Data and Safety Monitoring Boards for the VITALITY trial (Vitamin D for Adolescents with HIV to

reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195); and unpaid work as a Programme Committee member for the Vitamin D Workshop. All other authors declare that they have no competing interests.

Patient consent for publication: Not applicable.

Ethics approval: The study was approved by institutional review boards of the Mongolian Ministry of Health, Mongolian National University, and Harvard T. H. Chan School of Public Health (IRB # 14-0513). Participants and their parents/guardians provided written informed assent and consent, respectively, to take part in the trial before any study procedures were conducted.

Data availability statement: Anonymised data are available from corresponding authors upon reasonable request, subject to terms of IRB and regulatory approval.

Table 1: Participants' baseline characteristics by allocation and overall: main trial, exercise sub-study and spirometry sub-study

| | | Main Trial | | | Exercise Sub-study | | | Spirometry Sub-study | | |
|---|--------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| | | Placebo | Vitamin D | Total | Placebo | Vitamin D | Total | Placebo | Vitamin D | Total |
| | | N=4433 | N=4418 | N=8851 | N=330 | N=302 | N=632 | N=677 | N=666 | N=1343 |
| Mean age, years (s.d.) [range] | | 9.4 (1.6) [5.9 to 13.7] | 9.4 (1.6) [5.8 to 14.2] | 9.4 (1.6) [5.8 to 14.2] | 9.5 (1.5) [6.5 to 12.8] | 9.5 (1.5) [5.8 to 13.9] | 9.5 (1.5) [5.8 to 13.9] | 9.5 (1.5) [6.5 to 13.0] | 9.5 (1.6) [6.4 to 13.3] | 9.5 (1.6) [6.4 to 13.3] |
| Sex, n (%) | Female | 2224 (50.2%) | 2142 (48.5%) | 4366 (49.3%) | 166 (50.3%) | 141 (46.7%) | 307 (48.6%) | 325 (48.0%) | 333 (50.0%) | 658 (49.0%) |
| | Male | 2209 (49.8%) | 2276 (51.5%) | 4485 (50.7%) | 164 (49.7%) | 161 (53.3%) | 325 (51.4%) | 352 (52.0%) | 333 (50.0%) | 685 (51.0%) |
| Ethnic origin | Khalkh, n (%) | 4103 (92.6%) | 4062 (91.9%) | 8165 (92.2%) | 300 (90.9%) | 275 (91.1%) | 575 (91.0%) | 628 (92.8%) | 607 (91.1%) | 1235 (92.0%) |
| | Other, n (%) | 330 (7.4%) | 356 (8.1%) | 686 (7.8%) | 30 (9.1%) | 27 (8.9%) | 57 (9.0%) | 49 (7.2%) | 59 (8.9%) | 108 (8.0%) |
| Parental education ⁽¹⁾ | Secondary school or lower, n (%) | 2457 (55.4%) | 2401 (54.3%) | 4858 (54.9%) | 201 (60.9%) | 171 (56.6%) | 372 (58.9%) | 417 (61.6%) | 398 (59.8%) | 815 (60.7%) |
| | University/polytechnic, n (%) | 1976 (44.6%) | 2017 (45.7%) | 3993 (45.1%) | 129 (39.1%) | 131 (43.4%) | 260 (41.1%) | 260 (38.4%) | 268 (40.2%) | 528 (39.3%) |
| Type of residence | House with central heating, n (%) | 1083 (24.4%) | 1110 (25.1%) | 2193 (24.8%) | 62 (18.8%) | 54 (17.9%) | 116 (18.4%) | 100 (14.8%) | 99 (14.9%) | 199 (14.8%) |
| | Ger (Yurt), n (%) | 1628 (36.7%) | 1643 (37.2%) | 3271 (37.0%) | 112 (33.9%) | 106 (35.1%) | 218 (34.5%) | 277 (40.9%) | 290 (43.5%) | 567 (42.2%) |
| Home ownership, n (%) | House without central heating, n (%) | 1722 (38.8%) | 1665 (37.7%) | 3387 (38.3%) | 156 (47.3%) | 142 (47.0%) | 298 (47.2%) | 300 (44.3%) | 277 (41.6%) | 577 (43.0%) |
| | No | 963 (21.7%) | 925 (20.9%) | 1888 (21.3%) | 77 (23.3%) | 55 (18.2%) | 132 (20.9%) | 164 (24.2%) | 157 (23.6%) | 321 (23.9%) |
| | Yes | 3470 (78.3%) | 3493 (79.1%) | 6963 (78.7%) | 253 (76.7%) | 247 (81.8%) | 500 (79.1%) | 513 (75.8%) | 509 (76.4%) | 1022 (76.1%) |
| Mean monthly household income, US dollars (s.d.) ⁽²⁾ | | 845.8 (603.7) | 850.6 (553.8) | 848.2 (579.3) | 769.5 (411.6) | 844.1 (515.3) | 805.1 (465.2) | 751.5 (441.2) | 778.0 (427.8) | 764.6 (434.7) |
| Calcium intake ⁽²⁾ | <500 mg/day, n (%) | 2628 (64.6%) | 2599 (63.7%) | 5227 (64.2%) | 190 (63.8%) | 179 (63.3%) | 369 (63.5%) | 423 (63.4%) | 435 (66.1%) | 858 (64.8%) |
| | ≥500 mg/day, n (%) | 1437 (35.4%) | 1481 (36.3%) | 2918 (35.8%) | 108 (36.2%) | 104 (36.7%) | 212 (36.5%) | 244 (36.6%) | 223 (33.9%) | 467 (35.2%) |
| Mean BMI-for-age z-score (s.d.) ⁽²⁾ | | 0.2 (1.1) | 0.2 (1.0) | 0.2 (1.1) | 0.2 (1.1) | 0.1 (1.1) | 0.2 (1.1) | 0.1 (1.0) | 0.1 (1.1) | 0.1 (1.0) |
| Mean height-for-age z-score (s.d.) ⁽²⁾ | | -0.3 (1.0) | -0.3 (1.0) | -0.3 (1.0) | -0.3 (1.0) | -0.3 (1.1) | -0.3 (1.0) | -0.4 (0.9) | -0.3 (1.0) | -0.4 (1.0) |
| Mean serum 25(OH)D, nmol/L (s.d.) ^(2,3) | | 29.7 (10.5) | 29.5 (10.5) | 29.7 (10.5) | 28.6 (11.5) | 27.5 (10.5) | 28.1 (11.0) | 28.5 (10.5) | 28.1 (10.7) | 28.3 (10.6) |
| Serum 25(OH)D category ^(2,3) | <25 nmol/L, n (%) | 1424 (32.1%) | 1395 (31.6%) | 2819 (31.8%) | 126 (38.2%) | 116 (38.4%) | 242 (38.3%) | 253 (37.4%) | 232 (34.8%) | 485 (36.1%) |
| | 25-49.9 nmol/L, n (%) | 2809 (63.4%) | 2827 (64.0%) | 5636 (63.7%) | 189 (57.3%) | 174 (57.6%) | 363 (57.4%) | 399 (58.9%) | 408 (61.3%) | 807 (60.1%) |
| | 50-74.9 nmol/L, n (%) | 193 (4.4%) | 187 (4.2%) | 380 (4.3%) | 14 (4.2%) | 11 (3.6%) | 25 (4.0%) | 25 (3.7%) | 26 (3.9%) | 51 (3.8%) |
| | ≥75 nmol/L, n (%) | 7 (0.2%) | 9 (0.2%) | 16 (0.2%) | 1 (0.3%) | 1 (0.3%) | 2 (0.3%) | - | - | - |
| Mean maximal grip strength, kg (s.d.) ⁽²⁾ | | 12.0 (4.0) | 12.0 (4.0) | 12.0 (4.0) | 12.2 (3.9) | 12.4 (3.8) | 12.3 (3.9) | 12.0 (3.9) | 12.3 (4.1) | 12.1 (4.0) |
| Mean standing long jump distance, m (s.d.) ⁽²⁾ | | 107.9 (21.8) | 108.2 (22.6) | 108.0 (22.2) | 106.7 (21.6) | 108.8 (21.2) | 107.7 (21.5) | 107.4 (21.7) | 107.9 (23.0) | 107.6 (22.4) |

| | | Main Trial | | | Exercise Sub-study | | | Spirometry Sub-study | | |
|--|--|------------|-----------|--------|--------------------|------------|------------|----------------------|-----------|--------|
| | | Placebo | Vitamin D | Total | Placebo | Vitamin D | Total | Placebo | Vitamin D | Total |
| | | N=4433 | N=4418 | N=8851 | N=330 | N=302 | N=632 | N=677 | N=666 | N=1343 |
| Mean VO _{2peak} , mL/kg/min (s.d.) ⁽²⁾ | | - | - | - | 43.8 (3.1) | 44.2 (3.3) | 44.0 (3.2) | - | - | - |

Abbreviations: 25(OH)D, 25-hydroxyvitamin D. BMI, body mass index. IQR, inter-quartile range. S.d., standard deviation. SOS, speed of sound. US, United States. VO_{2peak}, peak oxygen consumption. **Footnotes.** (1), highest educational level attained by either parent; (2), missing values: monthly household income missing for 2 participants in the main trial (1 randomised to placebo, 1 to vitamin D); calcium intake missing for 706 participants in the main trial (368 randomised to placebo, 338 to vitamin D), 51 participants in the exercise sub-study (32 randomised to placebo, 19 to vitamin D) and 18 participants in the spirometry sub-study (18 randomised to placebo, 10 to vitamin D); BMI-for-age z-score missing for one participant in the main trial (randomised to placebo); height-for-age z-score missing for one participant in the main trial (randomised to placebo); 25(OH)D missing for 5 participants in the main trial (4 randomised to placebo, 1 to vitamin D); grip strength missing for 6 participants in the main trial (2 randomised to placebo, 4 to vitamin D) and 1 participant in the spirometry sub-study (randomised to placebo); long jump distance missing for 38 participants in the main trial (23 randomised to placebo, 15 to vitamin D), 2 participants in the exercise sub-study (both randomised to placebo) and 3 participants in the spirometry sub-study (2 randomised to placebo, 1 to vitamin D); VO₂ peak missing for 17 participants in the exercise sub-study (11 randomised to placebo, 6 to vitamin D). (3) baseline 25(OH)D values deseasonalised.

Table 2. Mean grip strength in main trial participants at 1-, 2- and 3-year follow-up by allocation: overall and by sub-group.

| | | | Vitamin D arm: mean strength, kg (s.d.) [n] | Placebo arm: mean strength, kg (s.d.) [n] | Adjusted mean difference (95% CI) (¹) | P for timepoint | Overall P | P for interaction |
|--|----------------|------------|---|---|--|--------------------|--------------|----------------------|
| Overall | | 1 year | 15.0 (4.9) [4,219] | 14.9 (4.8) [4,229] | 0.03 (-0.19, 0.25) | 0.79 | 0.999 | -- |
| | | 2 years | 17.1 (5.5) [3,802] | 17.3 (5.5) [3,829] | -0.09 (-0.31, 0.13) | 0.41 | | |
| | | 3 years | 20.0 (6.4) [4,074] | 20.0 (6.4) [4,054] | 0.01 (-0.21, 0.23) | 0.94 | | |
| By sex | Male | 1 year | 15.6 (5.0) [2,184] | 15.5 (4.8) [2,103] | 0.10 (-0.22, 0.42) | 0.53 | 0.90 | 0.55 |
| | | 2 years | 17.9 (5.8) [1,952] | 18.0 (5.8) [1,902] | -0.07 (-0.40, 0.26) | 0.67 | | |
| | | 3 years | 21.4 (7.2) [2,100] | 21.4 (7.1) [2,010] | -0.00 (-0.32, 0.32) | 0.99 | | |
| | Female | 1 year | 14.2 (4.7) [2,035] | 14.3 (4.7) [2,126] | -0.10 (-0.38, 0.18) | 0.47 | 0.48 | |
| | | 2 years | 16.2 (5.1) [1,850] | 16.5 (5.1) [1,927] | -0.19 (-0.47, 0.09) | 0.19 | | |
| | | 3 years | 18.6 (5.1) [1,974] | 18.7 (5.2) [2,044] | -0.10 (-0.38, 0.18) | 0.5 | | |
| By baseline 25(OH)D concentration ⁽²⁾ | <25 nmol/L | 1 year | 15.5 (5.2) [1,342] | 15.5 (5.3) [1,352] | 0.05 (-0.33, 0.44) | 0.78 | 0.73 | 0.75 |
| | | 2 years | 17.7 (5.9) [1,214] | 17.9 (6.0) [1,226] | -0.05 (-0.44, 0.34) | 0.81 | | |
| | | 3 years | 20.4 (6.7) [1,291] | 20.5 (6.7) [1,309] | 0.14 (-0.24, 0.53) | 0.47 | | |
| | ≥25 nmol/L | 1 year | 14.7 (4.7) [2,876] | 14.6 (4.5) [2,873] | 0.08 (-0.17, 0.33) | 0.53 | 0.77 | |
| | | 2 years | 16.8 (5.3) [2,587] | 16.9 (5.3) [2,600] | -0.05 (-0.31, 0.21) | 0.71 | | |
| | | 3 years | 19.8 (6.3) [2,782] | 19.8 (6.2) [2,742] | 0.02 (-0.24, 0.27) | 0.91 | | |
| By calcium intake | <500 mg/day | 1 year | 15.0 (4.8) [1,463] | 14.9 (4.8) [1,422] | 0.12 (-0.16, 0.40) | 0.41 | 0.51 | 0.20 |
| | | 2 years | 17.2 (5.6) [1,355] | 17.2 (5.6) [1,305] | -0.00 (-0.29, 0.29) | 0.998 | | |
| | | 3 years | 20.2 (6.4) [1,444] | 20.0 (6.5) [1,410] | 0.18 (-0.10, 0.46) | 0.21 | | |
| | ≥500 mg/day | 1 year | 14.8 (5.0) [2,572] | 15.0 (4.7) [2,596] | 0.12 (-0.16, 0.40) | 0.41 | 0.38 | |
| | | 2 years | 16.8 (5.5) [2,336] | 17.3 (5.5) [2,400] | -0.00 (-0.29, 0.29) | 0.998 | | |
| | | 3 years | 19.7 (6.5) [2,549] | 20.1 (6.2) [2,561] | 0.18 (-0.10, 0.46) | 0.21 | | |

Abbreviations: 25(OH)D, 25-hydroxyvitamin D. CI, confidence interval. S.d., standard deviation. N, number.

Footnotes. (1) adjusted for baseline value and school of attendance. (2) deseasonalised values.

Table 3. Mean long jump distance in main trial participants at 1-, 2- and 3-year follow-up by allocation: overall and by sub-group.

| | | | Vitamin D arm: mean distance, m (s.d.) [n] | Placebo arm: mean distance, m (s.d.) [n] | Adjusted mean difference (95% CI) (¹) | P for timepoint | Overall P | P for interaction |
|--|----------------|------------|--|--|--|--------------------|--------------|----------------------|
| Overall | | 1 year | 117.6 (22.4) [4,206] | 117.1 (21.9) [4,201] | 0.47 (-0.50, 1.45) | 0.34 | 0.33 | -- |
| | | 2 years | 124.2 (23.5) [3,790] | 124.0 (22.8) [3,809] | 0.42 (-0.57, 1.41) | 0.41 | | |
| | | 3 years | 132.0 (26.4) [4,012] | 131.3 (25.4) [3,988] | 0.76 (-0.22, 1.74) | 0.13 | | |
| By sex | Male | 1 year | 125.9 (22.2) [2,177] | 124.9 (21.6) [2,094] | 0.71 (-0.66, 2.08) | 0.31 | 0.17 | 0.04 ⁽²⁾ |
| | | 2 years | 134.2 (23.7) [1,944] | 133.1 (23.0) [1,895] | 1.10 (-0.30, 2.50) | 0.13 | | |
| | | 3 years | 144.4 (26.9) [2,065] | 142.9 (25.8) [1,984] | 1.32 (-0.06, 2.70) | 0.06 | | |
| | Female | 1 year | 108.8 (18.9) [2,029] | 109.4 (19.2) [2,107] | -0.40 (-1.53, 0.72) | 0.48 | 0.18 | |
| | | 2 years | 113.6 (18.0) [1,846] | 115.0 (18.6) [1,914] | -1.01 (-2.17, 0.14) | 0.09 | | |
| | | 3 years | 118.8 (18.3) [1,947] | 119.9 (18.9) [2,004] | -0.73 (-1.87, 0.41) | 0.21 | | |
| By baseline 25(OH)D concentration ⁽³⁾ | <25 nmol/L | 1 year | 119.2 (22.6) [1,339] | 119.3 (22.1) [1,343] | 0.32 (-1.42, 2.05) | 0.72 | 0.78 | 0.54 |
| | | 2 years | 125.6 (24.1) [1,212] | 126.1 (23.9) [1,219] | 0.51 (-1.26, 2.28) | 0.58 | | |
| | | 3 years | 133.3 (26.8) [1,268] | 133.3 (25.4) [1,288] | 0.80 (-0.96, 2.55) | 0.37 | | |
| | ≥25 nmol/L | 1 year | 116.9 (22.2) [2,866] | 116.1 (21.7) [2,854] | 0.65 (-0.51, 1.81) | 0.27 | 0.23 | |
| | | 2 years | 123.5 (23.2) [2,577] | 123.0 (22.2) [2,587] | 0.48 (-0.71, 1.67) | 0.43 | | |
| | | 3 years | 131.4 (26.2) [2,743] | 130.4 (25.3) [2,697] | 0.85 (-0.33, 2.02) | 0.16 | | |
| By calcium intake | <500 mg/day | 1 year | 117.7 (22.0) [1,461] | 117.3 (21.9) [1,412] | 0.34 (-0.90, 1.59) | 0.59 | 0.42 | 0.84 |
| | | 2 years | 124.3 (23.3) [1,355] | 123.8 (22.6) [1,301] | 0.55 (-0.72, 1.81) | 0.40 | | |
| | | 3 years | 131.8 (26.2) [1,422] | 131.1 (25.2) [1,382] | 0.65 (-0.60, 1.89) | 0.31 | | |
| | ≥500 mg/day | 1 year | 117.5 (22.8) [2,562] | 116.7 (21.9) [2,579] | 0.96 (-0.76, 2.67) | 0.28 | 0.49 | |
| | | 2 years | 124.0 (23.9) [2,329] | 124.3 (23.1) [2,385] | 0.31 (-1.44, 2.05) | 0.73 | | |
| | | 3 years | 132.5 (27.0) [2,510] | 131.7 (25.7) [2,527] | 1.30 (-0.42, 3.03) | 0.14 | | |

Abbreviations: 25(OH)D, 25-hydroxyvitamin D. CI, confidence interval. S.d., standard deviation. N, number.

Footnotes. (1) adjusted for baseline value and school of attendance. (2) after correction for multiple comparisons testing using the Benjamini & Hochberg method and a false discovery rate of 10%, this P-value for interaction did not remain significant (critical threshold of significance for family of P-values was <0.03). (3) deseasonalised values.

Table 4. Mean VO_{2peak} in exercise sub-study participants at 1-, 2- and 3-year follow-up by allocation: overall and by sub-group.

| | | | Vitamin D arm: mean VO_{2peak} ml/kg/min (s.d.) [n] | Placebo arm: mean VO_{2peak} ml/kg/min (s.d.) [n] | Adjusted mean difference (95% CI) ⁽¹⁾ | P for timepoint | Overall P | P for interaction |
|--|----------------|------------|--|--|--|--------------------|--------------|----------------------|
| Overall | | 1 year | 43.2 (3.7) [278] | 43.0 (3.4) [296] | 0.27 (-0.30, 0.84) | 0.36 | 0.28 | -- |
| | | 2 years | 41.9 (3.9) [268] | 41.9 (3.7) [289] | 0.20 (-0.37, 0.78) | 0.48 | | |
| | | 3 years | 41.3 (4.2) [268] | 41.3 (4.1) [286] | 0.05 (-0.53, 0.62) | 0.87 | | |
| By sex | Male | 1 year | 45.0 (3.1) [151] | 44.5 (3.1) [144] | 0.61 (-0.09, 1.32) | 0.09 | 0.06 | 0.06 |
| | | 2 years | 43.9 (3.1) [144] | 43.5 (3.3) [143] | 0.55 (-0.17, 1.26) | 0.13 | | |
| | | 3 years | 43.6 (3.0) [143] | 43.2 (3.8) [143] | 0.46 (-0.25, 1.18) | 0.20 | | |
| | Female | 1 year | 41.1 (3.3) [127] | 41.6 (3.1) [152] | -0.32 (-1.05, 0.40) | 0.38 | 0.47 | |
| | | 2 years | 39.7 (3.5) [124] | 40.2 (3.4) [146] | -0.40 (-1.13, 0.32) | 0.28 | | |
| | | 3 years | 38.7 (3.8) [125] | 39.4 (3.5) [143] | -0.68 (-1.41, 0.04) | 0.07 | | |
| By baseline 25(OH)D concentration ⁽²⁾ | <25 nmol/L | 1 year | 43.0 (4.2) [103] | 43.0 (3.2) [113] | -0.11 (-1.05, 0.83) | 0.82 | 0.44 | 0.06 |
| | | 2 years | 41.3 (4.0) [104] | 41.9 (3.7) [107] | -0.62 (-1.56, 0.32) | 0.20 | | |
| | | 3 years | 40.8 (4.6) [100] | 41.3 (4.1) [108] | -0.64 (-1.59, 0.30) | 0.18 | | |
| | ≥25 nmol/L | 1 year | 43.4 (3.5) [175] | 43.0 (3.5) [183] | 0.50 (-0.22, 1.22) | 0.18 | 0.050 | |
| | | 2 years | 42.4 (3.7) [164] | 41.8 (3.7) [182] | 0.71 (-0.02, 1.43) | 0.06 | | |
| | | 3 years | 41.6 (3.9) [168] | 41.3 (4.1) [178] | 0.46 (-0.26, 1.19) | 0.21 | | |
| By calcium intake | <500 mg/day | 1 year | 43.2 (3.9) [98] | 42.8 (3.5) [102] | 0.36 (-0.41, 1.14) | 0.36 | 0.18 | 0.60 |
| | | 2 years | 42.0 (4.1) [99] | 41.5 (3.7) [102] | 0.48 (-0.30, 1.25) | 0.23 | | |
| | | 3 years | 41.2 (4.4) [96] | 41.2 (4.2) [102] | 0.13 (-0.64, 0.91) | 0.74 | | |
| | ≥500 mg/day | 1 year | 43.5 (3.4) [169] | 43.3 (3.5) [174] | 0.27 (-0.68, 1.22) | 0.58 | 0.80 | |
| | | 2 years | 42.1 (3.4) [161] | 42.4 (3.7) [179] | 0.01 (-0.94, 0.96) | 0.99 | | |
| | | 3 years | 41.5 (3.9) [167] | 41.5 (4.0) [176] | 0.08 (-0.88, 1.03) | 0.88 | | |

Abbreviations: VO_{2peak} , peak oxygen consumption. 25(OH)D, 25-hydroxyvitamin D. CI, confidence interval. S.d., standard deviation. N, number.
Footnotes (1) adjusted for baseline value and school of attendance. (2) deseasonalised values.


Table 5. Spirometric outcomes at 3-year follow-up by allocation: overall and by sub-group

| | | Vitamin D arm: mean value (s.d.) [n] | Placebo arm: mean value (s.d.) [n] | Adjusted mean difference (95% CI) ⁽¹⁾ | P | P for interaction |
|--|-------------|--------------------------------------|------------------------------------|--|-------|---------------------|
| % predicted FEV1 | | | | | | |
| Overall | | 101.5 (11.1) [666] | 100.8 (11.0) [679] | 0.75 (-0.44, 1.93) | 0.22 | -- |
| By sex | Male | 99.5 (10.2) [333] | 100.0 (10.9) [354] | -0.45 (-2.05, 1.16) | 0.58 | 0.04 ⁽²⁾ |
| | Female | 103.4 (11.5) [333] | 101.7 (11.1) [325] | 2.06 (0.31, 3.81) | 0.021 | |
| By baseline 25(OH)D concentration ⁽³⁾ | <25 nmol/L | 102.0 (10.7) [232] | 101.0 (11.3) [253] | 1.31 (-0.67, 3.29) | 0.20 | 0.71 |
| | ≥25 nmol/L | 101.2 (11.3) [434] | 100.7 (10.8) [426] | 0.63 (-0.86, 2.12) | 0.41 | |
| By calcium intake | <500 mg/day | 101.2 (10.9) [223] | 100.7 (10.7) [244] | 0.73 (-0.73, 2.19) | 0.33 | 0.96 |
| | ≥500 mg/day | 102.1 (11.5) [435] | 101.1 (11.6) [425] | 0.88 (-1.26, 3.01) | 0.42 | |
| % predicted FVC | | | | | | |
| Overall | | 101.6 (11.2) [666] | 101.3 (11.5) [677] | 0.34 (-0.88, 1.55) | 0.59 | -- |
| By sex | Male | 100.2 (10.0) [333] | 101.5 (10.9) [352] | -1.13 (-2.71, 0.46) | 0.16 | 0.017 |
| | Female | 103.0 (12.1) [333] | 101.2 (12.1) [325] | 1.82 (-0.05, 3.70) | 0.06 | |
| By baseline 25(OH)D concentration ⁽³⁾ | <25 nmol/L | 102.2 (11.5) [232] | 101.0 (11.9) [253] | 1.36 (-0.75, 3.46) | 0.21 | 0.34 |
| | ≥25 nmol/L | 101.3 (11.1) [434] | 101.5 (11.2) [424] | -0.07 (-1.57, 1.43) | 0.92 | |
| By calcium intake | <500 mg/day | 101.5 (11.2) [223] | 101.4 (11.4) [244] | 0.23 (-1.30, 1.77) | 0.77 | 0.87 |
| | ≥500 mg/day | 101.6 (11.3) [435] | 101.1 (11.6) [423] | 0.57 (-1.53, 2.68) | 0.59 | |
| % predicted FEV1/FVC | | | | | | |
| Overall | | 98.0 (6.3) [666] | 97.6 (6.4) [679] | 0.49 (-0.19, 1.17) | 0.16 | -- |
| By sex | Male | 97.0 (6.3) [333] | 96.2 (6.6) [353] | 0.72 (-0.25, 1.69) | 0.15 | 0.49 |
| | Female | 99.1 (6.2) [333] | 99.0 (6.0) [326] | 0.25 (-0.68, 1.18) | 0.60 | |
| By baseline 25(OH)D concentration ⁽³⁾ | <25 nmol/L | 97.9 (6.2) [232] | 98.4 (6.4) [254] | -0.27 (-1.40, 0.85) | 0.64 | 0.08 |
| | ≥25 nmol/L | 98.1 (6.4) [434] | 97.1 (6.4) [425] | 0.96 (0.10, 1.82) | 0.028 | |
| By calcium intake | <500 mg/day | 97.8 (6.4) [223] | 97.4 (6.6) [244] | 0.51 (-0.37, 1.38) | 0.26 | 0.99 |
| | ≥500 mg/day | 98.5 (6.3) [435] | 98.0 (6.0) [425] | 0.45 (-0.68, 1.58) | 0.43 | |
| % predicted PEFR | | | | | | |
| Overall | | 95.2 (14.1) [666] | 93.6 (13.6) [680] | 1.69 (0.21, 3.18) | 0.026 | -- |
| By sex | Male | 94.2 (13.4) [333] | 93.1 (14.0) [354] | 1.08 (-0.98, 3.13) | 0.30 | 0.33 |
| | Female | 96.3 (14.8) [333] | 94.1 (13.2) [326] | 2.42 (0.24, 4.59) | 0.030 | |
| By baseline 25(OH)D concentration ⁽³⁾ | <25 nmol/L | 96.0 (13.4) [232] | 93.5 (13.9) [254] | 2.67 (0.19, 5.15) | 0.035 | 0.47 |
| | ≥25 nmol/L | 94.8 (14.5) [434] | 93.6 (13.5) [426] | 1.30 (-0.58, 3.18) | 0.18 | |
| By calcium intake | <500 mg/day | 94.3 (13.9) [223] | 92.8 (13.2) [244] | 1.76 (0.93, 3.59) | 0.060 | 0.97 |
| | ≥500 mg/day | 97.1 (14.7) [435] | 95.1 (14.2) [426] | 1.47 (-1.18, 4.12) | 0.28 | |
| % predicted FEF25-75 | | | | | | |
| Overall | | 102.4 (21.9) [667] | 100.7 (21.8) [680] | 1.47 (1.19, 3.82) | 0.22 | -- |
| By sex | Male | 99.8 (21.2) [334] | 98.0 (22.2) [354] | 1.17 (-2.14, 4.48) | 0.49 | 0.73 |
| | Female | 105.0 (22.3) [333] | 103.6 (20.9) [326] | 2.11 (-1.20, 5.42) | 0.21 | |
| By baseline 25(OH)D concentration ⁽³⁾ | <25 nmol/L | 102.0 (21.6) [232] | 101.4 (21.7) [254] | 1.19 (-2.69, 5.08) | 0.55 | 0.79 |
| | ≥25 nmol/L | 102.7 (22.1) [435] | 100.3 (21.8) [426] | 1.84 (-1.14, 4.81) | 0.23 | |
| By calcium intake | <500 mg/day | 100.9 (20.2) [223] | 99.9 (21.8) [244] | 0.92 (-1.94, 3.77) | 0.53 | 0.55 |
| | ≥500 mg/day | 105.6 (24.9) [436] | 102.5 (21.7) [426] | 2.38 (-1.88, 6.65) | 0.27 | |

Abbreviations: 25(OH)D, 25-hydroxyvitamin D. number. S.d., standard deviation. FEV1, forced expiratory volume in 1 second. FVC, forced vital capacity. PEFR, peak expiratory flow rate. FEF25-75, forced mid-expiratory flow.

Footnotes (1) adjusted for school of attendance. (2) after correction for multiple comparisons testing using the Benjamini & Hochberg method and a false discovery rate of 10%, this P-value for interaction did not remain significant (critical threshold of significance for family of P-values was <0.007). (3) deseasonalised values.

Figure 1: Trial profile



References

1. Smith JJ, Eather N, Morgan PJ, et al. The health benefits of muscular fitness for children and adolescents: a systematic review and meta-analysis. *Sports Med* 2014;44(9):1209-23. doi: 10.1007/s40279-014-0196-4 [published Online First: 2014/05/03]
2. Garcia-Hermoso A, Ramirez-Campillo R, Izquierdo M. Is Muscular Fitness Associated with Future Health Benefits in Children and Adolescents? A Systematic Review and Meta-Analysis of Longitudinal Studies. *Sports Med* 2019;49(7):1079-94. doi: 10.1007/s40279-019-01098-6 [published Online First: 2019/04/07]
3. Raghuvveer G, Hartz J, Lubans DR, et al. Cardiorespiratory Fitness in Youth: An Important Marker of Health: A Scientific Statement From the American Heart Association. *Circulation* 2020;142(7):e101-e18. doi: 10.1161/CIR.0000000000000866 [published Online First: 2020/07/21]
4. Garcia-Hermoso A, Ramirez-Velez R, Garcia-Alonso Y, et al. Association of Cardiorespiratory Fitness Levels During Youth With Health Risk Later in Life: A Systematic Review and Meta-analysis. *JAMA pediatrics* 2020;174(10):952-60. doi: 10.1001/jamapediatrics.2020.2400 [published Online First: 2020/09/02]
5. Ceglia L. Vitamin D and its role in skeletal muscle. *Current opinion in clinical nutrition and metabolic care* 2009;12(6):628-33. doi: 10.1097/MCO.0b013e328331c707 [published Online First: 2009/09/23]
6. Lykkedegn S, Sorensen GL, Beck-Nielsen SS, et al. The impact of vitamin D on fetal and neonatal lung maturation. A systematic review. *Am J Physiol Lung Cell Mol Physiol* 2015;308(7):L587-602. doi: 10.1152/ajplung.00117.2014 [published Online First: 2015/01/18]
7. Hunter L, Ferguson R, McDevitt H. Vitamin D deficiency cardiomyopathy in Scotland: a retrospective review of the last decade. *Arch Dis Child* 2020;105(9):853-56. doi: 10.1136/archdischild-2019-317794 [published Online First: 2020/03/04]
8. Roth DE, Abrams SA, Aloia J, et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. *Ann N Y Acad Sci* 2018;1430(1):44-79. doi: 10.1111/nyas.13968 [published Online First: 2018/09/19]
9. Voortman T, van den Hooven EH, Heijboer AC, et al. Vitamin D deficiency in school-age children is associated with sociodemographic and lifestyle factors. *J Nutr* 2015;145(4):791-8. doi: 10.3945/jn.114.208280 [published Online First: 2015/04/04]
10. Middelkoop K, Walker N, Stewart J, et al. Prevalence and Determinants of Vitamin D Deficiency in 1825 Cape Town Primary Schoolchildren: A Cross-Sectional Study. *Nutrients* 2022;14(6):1263. doi: <https://doi.org/10.3390/nu14061263>
11. Bater J, Bromage S, Jambal T, et al. Prevalence and Determinants of Vitamin D Deficiency in 9595 Mongolian Schoolchildren: A Cross-Sectional Study. *Nutrients* 2021;13(11) doi: 10.3390/nu13114175 [published Online First: 2021/11/28]
12. Bjarnadottir A, Kristjansdottir AG, Hrafnkelsson H, et al. Insufficient autumn vitamin D intake and low vitamin D status in 7-year-old Icelandic children. *Public Health Nutr* 2015;18(2):208-17. doi: 10.1017/S1368980013003558 [published Online First: 2014/01/31]
13. Valtuena J, Gracia-Marco L, Huybrechts I, et al. Cardiorespiratory fitness in males, and upper limbs muscular strength in females, are positively related with 25-hydroxyvitamin D plasma concentrations in European adolescents: the HELENA

- study. *QJM* 2013;106(9):809-21. doi: 10.1093/qjmed/hct089 [published Online First: 2013/05/10]
14. Yao TC, Tu YL, Chang SW, et al. Serum 25-hydroxyvitamin D levels in relation to lung function and exhaled nitric oxide in children. *J Pediatr* 2014;165(6):1098-103 e1. doi: 10.1016/j.jpeds.2014.08.048 [published Online First: 2014/10/06]
 15. Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* 2014;99(11):4336-45. doi: 10.1210/jc.2014-1742 [published Online First: 2014/07/18]
 16. Bezrati I, Ben Fradj MK, Hammami R, et al. A single mega dose of vitamin D(3) improves selected physical variables in vitamin D-deficient young amateur soccer players: a randomized controlled trial. *Appl Physiol Nutr Metab* 2020;45(5):478-85. doi: 10.1139/apnm-2019-0525 [published Online First: 2019/10/10]
 17. Ward KA, Das G, Roberts SA, et al. A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females. *J Clin Endocrinol Metab* 2010;95(10):4643-51. doi: 10.1210/jc.2009-2725 [published Online First: 2010/07/16]
 18. Thams L, Hvid LG, Stounbjerg NG, et al. Vitamin D supplementation and increased dairy protein intake do not affect muscle strength or physical function in healthy 6-8-year-old children: the D-pro randomized trial. *European journal of nutrition* 2022;61(7):3613-23. doi: 10.1007/s00394-022-02912-0 [published Online First: 2022/06/02]
 19. Mortensen C, Molgaard C, Hauger H, et al. Winter vitamin D(3) supplementation does not increase muscle strength, but modulates the IGF-axis in young children. *European journal of nutrition* 2019;58(3):1183-92. doi: 10.1007/s00394-018-1637-x [published Online First: 2018/02/17]
 20. Wright CS, Laing EM, Pollock NK, et al. Serum 25-Hydroxyvitamin D and Intact Parathyroid Hormone Influence Muscle Outcomes in Children and Adolescents. *J Bone Miner Res* 2018;33(11):1940-47. doi: 10.1002/jbmr.3550 [published Online First: 2018/07/13]
 21. Dubnov-Raz G, Livne N, Raz R, et al. Vitamin D Supplementation and Physical Performance in Adolescent Swimmers. *Int J Sport Nutr Exerc Metab* 2015;25(4):317-25. doi: 10.1123/ijsnem.2014-0180 [published Online First: 2014/09/10]
 22. El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. *J Clin Endocrinol Metab* 2006;91(2):405-12. doi: 10.1210/jc.2005-1436
 23. Ganmaa D, Uyanga B, Zhou X, et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. *N Engl J Med* 2020;383(4):359-68. doi: 10.1056/NEJMoa1915176 [published Online First: 2020/07/25]
 24. Ganmaa D, Bromage S, Khudyakov P, et al. Influence of Vitamin D Supplementation on Growth, Body Composition, and Pubertal Development Among School-aged Children in an Area With a High Prevalence of Vitamin D Deficiency: A Randomized Clinical Trial. *JAMA pediatrics* 2023;177(1):32-41. doi: 10.1001/jamapediatrics.2022.4581 [published Online First: 2022/11/29]
 25. Ganmaa D, Khudyakov P, Buyanjargal U, et al. Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial. *The lancet Diabetes & endocrinology* 2024;12(1):29-38. doi: 10.1016/S2213-8587(23)00317-0 [published Online First: 2023/12/05]

26. Bromage S, Daria T, Lander RL, et al. Diet and Nutrition Status of Mongolian Adults. *Nutrients* 2020;12(5) doi: 10.3390/nu12051514 [published Online First: 2020/05/28]
27. Espana-Romero V, Artero EG, Santaliesra-Pasias AM, et al. Hand span influences optimal grip span in boys and girls aged 6 to 12 years. *J Hand Surg Am* 2008;33(3):378-84. doi: 10.1016/j.jhsa.2007.11.013 [published Online First: 2008/03/18]
28. Castro-Pinero J, Ortega FB, Artero EG, et al. Assessing muscular strength in youth: usefulness of standing long jump as a general index of muscular fitness. *J Strength Cond Res* 2010;24(7):1810-7. doi: 10.1519/JSC.0b013e3181ddb03d [published Online First: 2010/06/18]
29. Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med* 2019;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST [published Online First: 2019/10/16]
30. Sempos CT, Betz JM, Camara JE, et al. General Steps to Standardize the Laboratory Measurement of Serum Total 25-Hydroxyvitamin D. *J AOAC Int* 2017;100(5):1230-33. doi: 10.5740/jaoacint.17-0259 [published Online First: 2017/08/03]
31. Matsuzaka A, Takahashi Y, Yamazoe M, et al. Validity of the Multistage 20-M Shuttle-Run Test for Japanese Children, Adolescents, and Adults. *Pediatric exercise science* 2004;113-25.
32. de Onis M, Onyango AW, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. *Bulletin of the World Health Organization* 2007;85(9):660-7. doi: 10.2471/blt.07.043497 [published Online First: 2007/11/21]
33. Sachs MC, Shoben A, Levin GP, et al. Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: the Multi-Ethnic Study of Atherosclerosis. *Am J Clin Nutr* 2013;97(6):1243-51. doi: 10.3945/ajcn.112.054502 [published Online First: 2013/04/26]
34. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *J Roy Stat Soc B Met* 1995;57(1):289-300.
35. Middelkoop K, Micklesfield LK, Hemmings S, et al. Influence of vitamin D supplementation on muscle strength and exercise capacity in South African schoolchildren: a randomised controlled trial (ViDiKids). *MedRxiv* 2024
36. Middelkoop K, Stewart J, Walker N, et al. Vitamin D Supplementation to Prevent Tuberculosis Infection in South African Schoolchildren: Multicentre Phase 3 Double-Blind Randomised Placebo-Controlled Trial (ViDiKids). *Int J Infect Dis* 2023;134:63-70. doi: 10.1016/j.ijid.2023.05.010 [published Online First: 2023 May 19]
37. Middelkoop K, Micklesfield LK, Walker N, et al. Influence of vitamin D supplementation on bone mineral content, bone turnover markers and fracture risk in South African schoolchildren: multicentre double-blind randomised placebo-controlled trial (ViDiKids). *J Bone Miner Res* 2024 doi: <https://doi.org/10.1093/jbmr/zjae007> [published Online First: 10 January 2024]
38. Middelkoop K, Micklesfield LK, Stewart J, et al. Influence of Vitamin D Supplementation on Growth, Body Composition, Pubertal Development and Spirometry in South African Schoolchildren: A Randomised Controlled Trial (ViDiKids). *BMJ Paediatr Open*, in press 2024
39. Wang MT, Bolland MJ, Grey A. Reporting of Limitations of Observational Research. *JAMA Intern Med* 2015;175(9):1571-2. doi: 10.1001/jamainternmed.2015.2147 [published Online First: 2015/06/09]